VTVT

vTv Therapeutics Inc
0.89
0.00 (0.0%)
0.89
Volume 0
Bid Price 0.87
Ask Price 1.08
News -
Day High

Low
0.382

52 Week Range

High
1.40

Day Low
Company Name Stock Ticker Symbol Market Type
vTv Therapeutics Inc VTVT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.89 04:01:34
Open Price Low Price High Price Close Price Prev Close
0.89
Trades Volume Avg Volume 52 Week Range
0 0 - 0.382 - 1.40
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.89 USD

Period:

Draw Mode:

vTv Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 72.52M 81.48M 44.87M $ 4.01M $ -3.16M -0.22 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 622.00k 0.30%

more financials information »

vTv Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTVT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.940.9794140.890.92255843,362-0.05-5.32%
1 Month0.8151.050.77010.931789766,7150.0759.2%
3 Months0.861.050.650.809566768,8900.033.49%
6 Months1.221.400.650.996804490,881-0.33-27.05%
1 Year0.71961.400.3820.7571095339,5450.170423.68%
3 Years3.845.130.3822.561,416,932-2.95-76.82%
5 Years6.897.260.3822.521,301,705-6.00-87.08%

vTv Therapeutics Description

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.